Bacteriocin-mediated competition in cystic fibrosis lung infections

Proceedings of the Royal Society B: Biological Sciences

Volumn 282, Issue 1814, 2015, Pages

  Ghoul, Melanie ^a   West, Stuart A ^a   Johansen, Helle Krogh ^b,c   Molin, Søren ^c,d   Harrison, Odile B ^a   Maiden, Martin C J ^a   Bruce, John B ^a   Griffin, Ashleigh S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b University of Copenhagen   (Denmark)

^c Chalmers University of Technology   (Denmark)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Bacteriocins; Competition; Cystic fibrosis; Pseudomonas aeruginosa; Pyocins

Indexed keywords

BACTERIUM; EXPERIMENTAL STUDY; GENE EXPRESSION; GENOME; GENOTYPE; IMMUNITY; INFECTIVITY; INHIBITION; PHENOTYPE; PUBLIC HEALTH; TOXIN;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

BACTERIOCIN; PYOCIN;

BACTERIAL GENOME; CYSTIC FIBROSIS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIOLOGY; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

BACTERIOCINS; CYSTIC FIBROSIS; GENOME, BACTERIAL; HUMANS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PYOCINS;

EID: 84940706892     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2015.0972     Document Type: Article

References (45)

1. Riley MA, Gordon DM. 1999 The ecological role of bacteriocins in bacterial competition. Trends Microbiol. 7, 129-133. (doi:10.1016/S0966- 842x(99)01459-6)
2. Michel-Briand Y, Baysse C. 2002 The pyocins of Pseudomonas aeruginosa. Biochimie 84, 499-510. (doi:10.1016/S0300-9084(02)01422-0)
3. Riley MA, Wertz JE. 2002 Bacteriocins: evolution, ecology, and application. Annu. Rev. Microbiol. 56, 117-137. (doi:10.1146/Annurev.Micro.56.012302. 161024)
4. Kerr B, Riley MA, Feldman MW, Bohannan BJM. 2002 Local dispersal promotes biodiversity in a real-life game of rock-paper-scissors. Nature 418, 171-174. (doi:10.1038/Nature00823)
5. Durrett R, Levin S. 1997 Allelopathy in spatially distributed populations. J. Theor. Biol. 185, 165-171. (doi:10.1006/Jtbi.1996.0292)
6. Kirkup BC, Riley MA. 2004 Antibiotic-mediated antagonism leads to a bacterial game of rock- paper-scissors in vivo. Nature 428, 412-414. (doi:10.1038/nature02429)
7. Parret AHA, De Mot R. 2002 Bacteria killing their own kind: novel bacteriocins of pseudomonas and other gamma-proteobacteria. Trends Microbiol. 10, 107-112. (doi:10.1016/S0966-842X(02)02307-7)
8. Heo YJ, Chung IY, Choi KB, Cho YH. 2007 R-type pyocin is required for competitive growth advantage between Pseudomonas aeruginosa strains. J. Microbiol. Biotechnol. 17, 180-185
9. Kohler T, Donner V, van Delden C. 2010 Lipopolysaccharide as shield and receptor for R- pyocin-mediated killing in Pseudomonas aeruginosa. J. Bacteriol. 192, 1921-1928. (doi:10.1128/Jb. 01459-09)
10. Uratani Y, Hoshino T. 1984 Pyocin-R1 inhibits active- transport in Pseudomonas aeruginosa and depolarizes membrane potential. J. Bacteriol. 157, 632-636.
11. Sano Y, Matsui H, Kobayashi M, Kageyama M. 1993 Molecular structures and functions of pyocin-S1 and pyocin-S2 in Pseudomonas aeruginosa. J. Bacteriol. 175,2907-2916.
12. Sano Y, Kageyama M. 1993 A novel transposon-like structure carries the genes for pyocin-Ap41, a Pseudomonas aeruginosa bacteriocin with a DNase domain homology to E2 group colicins. Mol. Gen. Genet. 237, 161-170.
13. Duport C, Baysse C, Michelbriand Y. 1995 Molecular characterization of pyocin S3, a novel S-type pyocin from Pseudomonas aeruginosa. J. Biol. Chem. 270, 8920-8927. (doi:10.1074/jbc. 270.15.8920)
14. Fyfe JAM, Harris G, Govan JRW. 1984 Revised pyocin typing method for Pseudomonas aeruginosa. J. Clin. Microbiol. 20, 47-50.
15. Scholl D, Cooley M, Williams SR, Gebhart D, Martin D, Bates A, Mandrell R. 2009 An engineered R-type pyocin is a highly specific and sensitive bactericidal agent for the food-borne pathogen Escherichia coli O157:H7. Antimicrob. Agents Ch. 53, 3074-3080. (doi:10.1128/Aac.01660-08)
16. Fegan M, Francis P, Hayward AC, Fuerst JA. 1991 Heterogeneity, persistence, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients. J. Clin. Microbiol. 29, 2151-2157.
17. Godard C, Plesiat P, Michel-Briand Y. 1993 Persistence of Pseudomonas aeruginosa strains in seven cystic fibrosis patients followed over 20 months. Eur. J. Med. 2, 117-120.
18. Marvig RL, Sommer LM, Molin S, Johansen HK. 2015 Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat. Genet. 47, 57-64. (doi:10.1038/ng.3148)
19. Jelsbak L et al. 2007 Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in lungs of cystic fibrosis patients. Infect. Immun. 75,2214-2224. (doi:10.1128/Iai.01282-06)
20. Marvig RL, Johansen HK, Molin S, Jelsbak L. 2013 Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators. PLoS Genet. 9, pArtn E1003741. (doi:10.1371/journal.pgen.1003741)
21. Biernaskie JM, Gardner A, West SA. 2013 Multicoloured greenbeards, bacteriocin diversity and the rock-paper-scissors game. J. Evol. Biol. 26, 2081-2094. (doi:10.1111/Jeb.12222)
22. Chao L, Levin BR. 1981 Structured habitats and the evolution of anticompetitor toxins in bacteria. Proc. Natl Acad. Sci. USA 78, 6324-6328. (doi:10.1073/ Pnas.78.10.6324)
23. Czaran TL, Hoekstra RF, Pagie L. 2002 Chemical warfare between microbes promotes biodiversity. Proc. Natl Acad. Sci. USA 99, 786-790. (doi:10. 1073/Pnas.012399899)
24. Denayer S, Matthijs S, Cornelis P. 2007 Pyocin S2 (Sa) kills Pseudomonas aeruginosa strains via the FpvA type I ferripyoverdine receptor. J. Bacteriol. 189,7663-7668. (doi:10.1128/Jb.00992-07)
25. Jolley KA, Maiden MCJ. 2010 BIGSdb: scalable analysis of bacterial genome variation at the population level. BMC Bioinform. 11. pArtn 595. (doi:10.1186/1471-2105-11-595)
26. Ernst RK et al. 2003 Genome mosaicism is conserved but not unique in Pseudomonas aeruginosa isolates from the airways of young children with cystic fibrosis. Environ. Microbiol. 5, 1341-1349. (doi:10.1046/J.1462-2920.2003.00518.X)
27. Eberl L, Tummler B. 2004 Pseudomonas aeruginosa and Burkholderia cepacia in cystic fibrosis: genome evolution, interactions and adaptation. Int. J. Med. Microbiol. 294, 123-131. (doi:10.1016/j.ijmm.2004.06.022)
28. Romling U, Fiedler B, Bosshammer J, Grothues D, Greipel J, von der Hardt H, Tummler B. 1994 Epidemiology of chronic Pseudomonas aeruginosa infections in cystic fibrosis. J. Infectious Dis. 170, 1616-1621. (doi:10.1093/infdis/170.6.1616)
29. Tredgett MW, Doherty C, Govan JRW. 1990 Incidence of common pyocin types of Pseudomonas aeruginosa from patients with cystic fibrosis and chronic airways diseases. J. Med. Microbiol. 32, 169-172. (doi:10.1099/00222615-32-3-169)
30. Tummler B, Kiewitz C. 1999 Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections. Mol. Med. Today 5, 351-358. (doi:10.1016/S1357-4310(99)01506-3)
31. Yang L, Jelsbak L, Molin S. 2011 Microbial ecology and adaptation in cystic fibrosis airways. Environ. Microbiol. 13, 1682-1689. (doi:10.1111/J.1462- 2920.2011.02459.X)
32. Bakkal S, Robinson SM, Ordonez CL, Waltz DA, Riley MA. 2010 Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients. Microbiology 156, 2058-2067. (doi:10.1099/Mic.0.036848-0)
33. Blackwell CC, Winstanley FP, Brunton WAT. 1982 Sensitivity of thermophilic campylobacters to R-type pyocins of Pseudomonas aeruginosa. J. Med. Microbiol. 15,247-251. (doi:10.1099/00222615-15-2-247)
34. Campagnari AA, Karalus R, Apicella M, Melaugh W, Lesse AJ, Gibson BW. 1994 Use of pyocin to select a Haemophilus ducreyi variant defective in lipooligosaccharide biosynthesis. Infect. Immun. 62, 2379-2386.
35. Morse SA, Jones BV, Lysko PG. 1980 Pyocin 8 inhibition of Neisseria gonorrhoeae—mechanism of action. Antimicrob. Agents Ch. 18, 416-423. (doi:10.1128/AAC.18.3.416)
36. Williams SR, Gebhart D, Martin DW, Scholl D. 2008 Retargeting R-type pyocins to generate novel bactericidal protein complexes. Appl. Environ. Microb. 74, 3868-3876. (doi:10.1128/Aem.00141-08)
37. Waite RD, Curtis MA. 2009 Pseudomonas aeruginosa PAO1 pyocin production affects population dynamics within mixed-culture biofilms. J. Bacteriol. 191, 1349-1354. (doi:10.1128/Jb.01458-08)
38. Brazas MD, Hancock REW. 2005 Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa. Antimicrob. Agents Ch. 49, 3222-3227. (doi:10.1128/Aac.49.8.3222-3227.2005)
39. Chang W, Small DA, Toghrol F, Bentley WE. 2005 Microarray analysis of Pseudomonas aeruginosa reveals induction of pyocin genes in response to hydrogen peroxide. BMC Genom. 6, pArtn 115. (doi:10.1186/1471-2164-6-115)
40. Jacob F. 1954 Biosynthèse induite et mode d’action d’une pyocine, antibiotique de Pseudomonas pyocyanea. Ann. I Pasteur Paris 86, 149-160.
41. Brown MRW, Anwar H, Lambert PA. 1984 Evidence that mucoid Pseudomonas aeruginosa in the cystic fibrosis lung grows under iron-restricted conditions. FEMS Microbiol. Lett. 21, 113-117. (doi:10.1111/J.1574-6968.1984.Tb00195.X)
42. Baysse C, Meyer JM, Plesiat P, Geoffroy V, Michel-Briand Y, Cornelis P. 1999 Uptake of pyocin S3 occurs through the outer membrane ferripyoverdine type II receptor of Pseudomonas aeruginosa. J. Bacteriol. 181, 3849-3851.
43. Elfarash A, Dingemans J, Ye L, Hassan AA, Craggs M, Reimmann C, Thomas MS, Cornelis P. 2014 Poreforming pyocin S5 utilizes the FptA ferripyochelin receptor to kill Pseudomonas aeruginosa. Microbiology 160, 261-269. (doi:10.1099/mic.0. 070672-0)
44. Ghequire MG, De Mot R. 2014 Ribosomally encoded antibacterial proteins and peptides from Pseudomonas. FEMS Microbiol. Rev. 38, 523-568. (doi:10.1111/1574-6976.12079)
45. Cascales E, Buchanan SK, Duche D, Kleanthous C, Lloubes R, Postle K, Riley M, Slatin S, Cavard D. 2007 Colicin biology. Microbiol. Mol. Biol. Rev. 71, 158-229. (doi:10.1128/Mmbr.00036-06)